Dave Ricks, Lilly CEO
"Lilly, along with the pharmaceutical industry, is committed to work with the rest of the health care system to fix the problem of drug costs."
At Lilly, we're in the early phases of a prolonged period of volume-driven growth for the company. We see ample opportunity to execute better, move faster and deliver new medicines that improve the lives of millions of people.
In our vision for the future, we see incredible possibilities in the science to tackle the most significant health challenges our aging societies face and provide valuable new treatments for doctors and patients. New therapeutic modalities and biologic understanding are opening up new target possibilities – and Lilly is embracing them.
Here are four reasons to believe in what we're doing:
Lilly is helping more patients around the world. We’ve launched 10 new molecules in the last five years. Lilly is well positioned for the coming years to reach more people who can benefit from our medicines.
Replenishing our pipeline in our core areas is our key focus in the next several years. We will add more assets to Phase 3, both from Lilly’s own labs and from outside, that show opportunities to be first or best in large diseases with high unmet need and to change the treatment standard for the better.
We believe we have chosen five therapeutic areas that matter – diabetes, cancer, immunology, pain and neurodegeneration. These include four of the six fastest growing, according to the latest data, and we have deep expertise in these areas. We believe Lilly is as capable as anyone of finding and delivering breakthrough innovation.
Our company continues to take the steps necessary to streamline our structure and focus exclusively on innovative human medicines to make life better for people around the world.
To listen to Dave Ricks' full remarks at the 2019 J.P. Morgan Healthcare Conference, visit us here. Lilly's actual results may turn out different from projections and forward-looking statements above, which are based on current expectations.